Apellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Analysts at Royal Bank of Canada

Stock analysts at Royal Bank of Canada began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) in a report issued on Friday, MarketBeat reports. The brokerage set a "sector perform" rating and a $25.00 price target on the stock. Royal Bank of Canada's price objective would suggest a potential downside of 6.30% from the company's previous close.

A number of other research analysts have also recently weighed in on APLS. Wells Fargo & Company dropped their target price on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an "equal weight" rating on the stock in a research note on Tuesday, September 24th. UBS Group dropped their price target on Apellis Pharmaceuticals from $85.00 to $83.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. HC Wainwright cut their target price on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a "buy" rating for the company in a research report on Friday, August 2nd. Robert W. Baird lowered their price target on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an "outperform" rating on the stock in a research report on Monday, September 23rd. Finally, Wedbush raised their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, August 9th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $65.41.

Apellis Pharmaceuticals Stock Down 3.3 %

Apellis Pharmaceuticals stock traded down $0.90 during midday trading on Friday, hitting $26.68. 1,122,374 shares of the stock were exchanged, compared to its average volume of 1,685,060. Apellis Pharmaceuticals has a 52-week low of $26.28 and a 52-week high of $73.80. The business's 50-day moving average price is $33.22 and its 200-day moving average price is $38.63. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of -7.71 and a beta of 0.87. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. Apellis Pharmaceuticals's quarterly revenue was up 110.2% compared to the same quarter last year. During the same period last year, the company posted ($1.02) earnings per share. On average, research analysts expect that Apellis Pharmaceuticals will post -1.37 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the firm's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 6.80% of the company's stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in APLS. Future Financial Wealth Managment LLC bought a new position in shares of Apellis Pharmaceuticals during the 1st quarter valued at about $29,000. Hennion & Walsh Asset Management Inc. grew its position in Apellis Pharmaceuticals by 14.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 14,068 shares of the company's stock valued at $827,000 after acquiring an additional 1,766 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Apellis Pharmaceuticals by 94.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 115,453 shares of the company's stock valued at $6,786,000 after acquiring an additional 56,178 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Apellis Pharmaceuticals by 254.5% during the first quarter. Principal Financial Group Inc. now owns 84,604 shares of the company's stock worth $4,973,000 after acquiring an additional 60,741 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Apellis Pharmaceuticals in the 1st quarter worth approximately $3,218,000. Hedge funds and other institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).